Modifiedblue cross blue shield - louisianaPolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

Defines coverage criteria for HIV screening, diagnostic confirmation, nucleic acid testing, viral load monitoring, and genotypic/phenotypic resistance testing for members of Blue Cross and Blue Shield of Louisiana.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyHuman Immunodeficiency Virus (HIV) coverage criteria — testing, monitoring, and resistance assays

Policy CodePolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)

Change TypeRevised coverage criteria and notesmaterial changes to screening and testing frequency

Effective DateMar 15, 2026

Next Review DateN/A

Key ActionOrder antigen/antibody combination screening for persons 11–65, use antibody differentiation after a positive screen, and document indication and timing per Note 1 and Note 2.

SourceLink

POLICY UPDATE CHANGES

New coverage criteria CC3, CC4, and CC9 were added addressing PrEP-related screening, antibody differentiation assays after positive screening, and exclusion of standalone antigen testing.

Frequency limits for antigen/antibody and NAAT testing were moved into a new Note 1: antibody and antigen/antibody testing no more often than every 90 days; NAAT no more often than once monthly.

New Note 2 enumerates risk factors that define elevated risk for HIV infection (MSM, partners with HIV, multiple partners, needle sharing, exchange sex, prior/concurrent STI/hepatitis/TB, sexual partners with high-risk or unknown history).

Initial & repeat (11-65)Antigen/antibody combination assay coverage

MonthlyNAAT frequency limit

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Antibody/antigen repeat limit

Not coveredStandalone antigen testing

Prior to doravirineGenotyping indication

>=1000Pregnancy VL threshold

Coverage Criteria

Covered indications

Covered when specified clinical conditions are met

Screening: For individuals 11 to 65 years of age, initial screening for HIV infection with an antigen/antibody combination assay meets coverage criteria.age 11-65

Repeat antigen/antibody testing should not be performed more often than once every 90 days (Note 1).

Repeat screening: For individuals 11 to 65 years of age, repeat antigen/antibody screening for HIV infection meets coverage criteria.age 11-65

See Note 1 for frequency limits (no more often than every 90 days).

Risk-based/PrEP screening: For individuals who will begin pre-exposure prophylaxis (PrEP), for individuals receiving PrEP, or for individuals with elevated risk factors for HIV infection, screening with an antigen/antibody combination assay or with a rapid antibody test meets coverage criteria.see Note 2 for risk factors

Post‑screen positive: For individuals for whom initial screening was positive for an HIV infection, the HIV-1/HIV-2 antibody differentiation assay meets coverage criteria.positive initial screen

See Note 1 for testing frequency guidance.

Nucleic acid testing (diagnostic): Qualitative or quantitative nucleic acid testing (NAT) for HIV-1 and HIV-2 meets coverage criteria when initial screening is positive, indeterminate, or when recent exposure is suspected or reported.positive/indeterminate screen or recent exposure

NAT should not be repeated more often than once every month (Note 1).

Genotyping/Phenotyping: HIV genotyping or phenotyping meets coverage criteria for specified clinical situations including prior to initiating doravirine therapy (genotyping and phenotyping required), treatment failure, suboptimal viral load reduction, noncompliance, recent infection (within 6 months), antiretroviral‑naïve individuals entering treatment, and certain pregnancy scenarios.clinical indications listed

Routine combined genotyping and phenotyping is not covered; genotyping/phenotyping for multidrug resistance or failing regimens is covered.

Viral load quantification (monitoring): Plasma quantification of HIV-1 or HIV-2 RNA meets coverage criteria for monitoring disease progression, monitoring response to antiretroviral therapy, infants younger than 18 months born to HIV-positive mothers, and for predicting maternal‑fetal transmission.clinical monitoring indications

Use the same assay platform for serial measurements; changes less than 0.5 log10 may reflect assay variability (see thresholds).

Coverage criteria for viral load monitoring and resistance testing

Covered when the following DHHS-recommended conditions are met

Initial evaluation and monitoring: Measure plasma viral load at entry into care, at ART initiation, within 4–8 weeks after start or regimen change, and then every 3–4 months for stable patients (interval may be extended to 6 months for adherent, stable patients).timing-based

From DHHS viral load monitoring recommendations; includes pregnancy guidance.

Genotypic resistance testing — initial/ART‑naïve: Genotypic resistance testing is recommended at entry into care to guide selection of initial ART; testing should not delay ART initiation and should include integrase testing if transmitted INSTI resistance is suspected or prior CAB‑LA use occurred.NA

DHHS recommends sending a sample for genotypic testing before ART when possible.

Resistance testing — virologic failure and ART‑experienced:

Diagnosis, Baseline, Monitoring, and Resistance Testing

Guidance summaries for when testing is recommended

Diagnostic testing and window‑period guidance: Select antibody, antigen/antibody, or NAT according to exposure timing and test window: antibody tests typically detect infection 23–90 days after exposure; rapid antigen/antibody finger‑stick 18–90 days; antigen/antibody lab venous 18–45 days; NAT 10–33 days. If initial test after exposure is negative, repeat testing after the appropriate window period. If an antibody test is positive, follow‑up NAT testing is required to confirm.

Sources: CDC; NAT may detect infection earlier than antibody/antigen tests.

Baseline viral load at diagnosis: Obtain quantitative HIV RNA (viral load) at entry into care to characterize infection stage and guide ART selection.

Recommended by IDSA, IAS, EACS, BHIVA.

Viral load monitoring after ART initiation: Assess adherence and measure HIV RNA within 4–8 weeks (IDSA recommends 2–4 weeks, no later than 8 weeks) after starting ART; continue monitoring every 4–8 weeks until suppression, then every 3 months for the first year and possibly every 6 months thereafter for stable patients.

New and revised coverage criteria (summarized)

Selected coverage criteria changes and relevant rules

CC3 (PrEP and elevated‑risk screening): For individuals who will begin pre‑exposure prophylaxis (PrEP), for individuals receiving PrEP, or for individuals with elevated risk factors for HIV infection, screening with an antigen/antibody combination assay or with a rapid antibody test MEETS COVERAGE CRITERIA.

Elevated risk factors enumerated in Note 2 (e.g., MSM, partner with HIV, multiple partners, needle sharing, exchange sex, prior/concurrent STI/hepatitis/TB, partners with high‑risk or unknown history).

CC4 (Post‑positive initial screen): For individuals with a positive initial screening result, the HIV‑1/HIV‑2 antibody differentiation assay MEETS COVERAGE CRITERIA.positive initial screen

See Note 1 for testing frequency guidance (antibody/antigen testing no more often than every 90 days).

CC9 (Antigen testing exclusion): HIV antigen testing performed independent of an antigen/antibody combination assay DOES NOT MEET COVERAGE CRITERIA.

The policy explicitly excludes HIV antigen testing performed independent of an antigen/antibody combination assay and considers routine combined genotyping and phenotyping to not meet coverage criteria. These exclusions are stated as discrete coverage determinations and may lead to claim denials when antigen testing is billed as a standalone service or when genotyping and phenotyping are ordered routinely without the covered clinical indications.

A decision-analytic model assessing point-of-care HIV RNA viral load testing to guide mode of delivery in pregnant women without prenatal care found the strategy produced more neonatal infections and higher costs compared with routine cesarean delivery for all. The model authors concluded that point-of-care viral load testing in that population was not cost-effective except in narrow parameter ranges, and the policy summarizes this as evidence that routine use of point-of-care viral load testing for delivery decision-making may have unfavorable clinical and economic outcomes.

The document notes that laboratory‑developed tests (LDTs) are regulated under CLIA as high‑complexity tests and are not approved or cleared by the FDA, but FDA approval is not required for clinical use. The policy does not broadly exclude LDTs from clinical use; instead it references FDA‑approved assays as examples while acknowledging the regulatory status of LDTs.

Standalone HIV antigen testing — defined as antigen testing performed independent of an antigen/antibody combination assay — is explicitly stated to NOT MEET COVERAGE CRITERIA and is listed among actions that may be denied if submitted as a separate service.

The policy states that routine combined genotyping and phenotyping is not covered. Genotypic testing alone is supported for specific clinical indications (e.g., at entry to care, virologic failure, or prior to certain drug choices), and phenotypic testing is reserved for complex multi‑drug resistance scenarios rather than as a routine paired test.

Within the supplied excerpts there are no additional explicit statements declaring other services as not medically necessary; coverage determinations focus on the enumerated exclusions and indications tied to clinical criteria and guideline recommendations.

In the provided excerpts there are no explicit ‘not medically necessary’ labels beyond the exclusions already noted (e.g., standalone antigen testing and routine combined genotyping/phenotyping). Coverage decisions should also defer to applicable government policies (NCDs/LCDs or state Medicaid) when conflicts exist.

Restating the policy exclusion: HIV antigen testing independent of antigen/antibody testing does not meet coverage criteria. This exclusion was added/affirmed in the recent revision and is a specific denial risk when antigen testing is billed outside an Ag/Ab algorithm.

Coding and Frequencies

Covered/Referenced CPT CodesCPT

86689	Antibody; HTLV or HIV antibody, confirmatory test (e.g., Western Blot)
86701	Antibody; HIV-1
86702	Antibody; HIV-2
86703	Antibody; HIV-1 and HIV-2, single result
87389	Infectious agent antigen detection by immunoassay technique (e.g., EIA, ELISA, FIA, IMCA), qualitative or semiquantitative; (see code group for HIV-specific codes)
87390	Infectious agent antigen detection by immunoassay; HIV-1 antigen(s) with HIV-1 and HIV-2 antibodies, single result
87391	Infectious agent antigen detection by immunoassay; HIV-2
87534	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
87535	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
87536	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed

1–10 of 17

1/2

Covered/Referenced HCPCS CodesHCPCS

G0432	Infectious agent antibody detection by enzyme immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (ELISA) technique, HIV-1 and/or HIV-2, screening
G0435	Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening
G0475	HIV antigen/antibody, combination assay, screening
S3645	HIV-1 antibody testing of oral mucosal transudate

Virologic change threshold

Virologic change thresholdChange must exceed at least 0.5 log10 (threefold) to be biologically relevant

Assay agreement threshold for virologic failure

Assay agreement threshold for virologic failure200 copies/mL

Viral load thresholds for resistance testing and action

Viral load thresholds for resistance testing and actionGuidance references thresholds commonly ranging from >200 copies/mL to ≥500-1,000 copies/mL depending on context (see DHHS, EACS, and BHIVA excerpts in policy).

Resistance testing viral load thresholds

Provider Actions and Authorization

Prior Authorization

No prior authorization requirement is specified for HIV resistance testing, viral load testing, or related HIV laboratory assays in this policy. Providers should follow medical necessity criteria and coverage indications when ordering tests.

Prior authorization: none specified — orders are governed by medical necessity criteria and applicable coverage indications.

Billing Rule

Codes Referenced for Authorization

For billing and authorization reference, use the applicable CPT/HCPCS codes listed in the policy when submitting claims or prior authorization requests. Reference the procedure code list to support medical necessity.

Relevant CPT/HCPCS examples: 87534, 87535, 87536, 87538, 87539, 87900, 87901, 87906, 0219U, G0432, G0433, G0435, G0475, S3645.

Background and Evidence Summary

HIV is an RNA retrovirus that primarily infects CD4+ immune cells. HIV‑1 is the globally dominant type, while HIV‑2 is less common and regionally concentrated. Viral load (plasma HIV‑1 or HIV‑2 RNA) quantification is used to stage disease, guide antiretroviral therapy, and monitor response; genotypic assays detect drug resistance mutations in key viral genes, and phenotypic assays measure the degree to which drugs inhibit viral replication. Serial viral load measurements should be performed on the same assay platform due to inter‑assay variability.

As noted in the evidence summary, a modeled evaluation of point‑of‑care viral load testing in pregnant women without prenatal care found higher neonatal infections and increased costs compared with routine cesarean delivery for all; the authors thus questioned the clinical and economic utility of point‑of‑care viral load testing to guide mode of delivery in that context.

Definitions

inv-41: HIV-1 / HIV-2

HIV-1 predominanceHIV-1 is the dominant subtype globally

HIV-2 characteristicsHIV-2 is less common, often milder clinically, and endemic in West Africa; HIV-2 may not be well detected by HIV-1 RNA assays

Diagnostic implicationUse antibody/antigen differentiation and specific testing strategies for suspected HIV-2; NATs for HIV-1 do not reliably detect HIV-2

inv-42: Genotypic assay

DefinitionGenotypic assays detect specific drug-resistance mutations in genes such as protease, reverse transcriptase, and integrase

PurposeUsed to predict resistance and guide selection of active antiretroviral drugs

Revision History

2026-03-15material_revisionLatest

Reviewed and updated policy; added new coverage criteria CC3 (PrEP/elevated-risk screening), CC4 (HIV-1/HIV-2 antibody differentiation after positive screen), and CC9 (exclusion of standalone antigen testing); moved testing frequency limits into new Note 1 and added Note 2 enumerating risk factors defining elevated risk.

2025-09-01revision

Reviewed and updated background, guidelines, and references; added antigen/antibody testing to screening criteria, clarified repeat testing limits (antigen/antibody no more than every 90 days; NAAT no more than once monthly), and reorganized related coverage items.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyHuman Immunodeficiency Virus (HIV) coverage criteria — testing, monitoring, and resistance assays

Policy CodePolicy AHS - M2116 - Human Immunodeficiency Virus (HIV)

Change TypeRevised coverage criteria and notesmaterial changes to screening and testing frequency

Effective DateMar 15, 2026

Next Review DateN/A

Key ActionOrder antigen/antibody combination screening for persons 11–65, use antibody differentiation after a positive screen, and document indication and timing per Note 1 and Note 2.

SourceLink

On This Page

Perform genotypic resistance testing in persons with virologic failure: generally for HIV RNA >200 copies/mL (stronger recommendation at >1,000 copies/mL; recommended consideration for 501–1,000 and 201–500 copies/mL per DHHS tiers). Testing should be performed while on ART or within 4 weeks of stopping non‑long‑acting agents. Consider phenotypic testing for complex multi‑drug resistance and include INSTI testing when INSTI exposure or failure is suspected.

HIV RNA thresholds specified

Long‑acting agents require testing regardless of time since discontinuation.

Resistance testing in pregnancy: Genotypic resistance testing should be performed before ART initiation in pregnant persons and in those entering pregnancy with detectable HIV RNA; ART should be initiated before results and modified if necessary when results are available.NA

Thresholds for performing testing: >500 to 1,000 copies/mL for standard genotypic assays; testing may be considered at lower levels but may be unsuccessful.

Alternative specimens for low/undetectable RNA: Proviral DNA or cellular viral RNA/DNA assays may be useful for resistance testing when plasma HIV RNA is undetectable or at low levels that impede genotypic testing.low/undetectable plasma RNA

Cited as useful when plasma‑based genotypic assays are unlikely to succeed.

Schedules referenced from IAS, IDSA, BHIVA guidance.

When to perform resistance/genotypic testing: Perform resistance testing at diagnosis (ideally), prior to treatment initiation (but do not delay ART), and at virologic failure preferably while on failing therapy. Routine availability is generally for VL >200–500 copies/mL; include RT and INSTI regions when indicated.

Recommendations from EACS, IAS, BHIVA, IDSA.

Management of low‑level viremia: For persistent low‑level viremia (50–200 copies/mL) assess adherence and toxicity; do not routinely change ART solely for low‑level viremia unless toxicity or intolerance is present.50–200 copies/mL

IAS and other societies recommend adherence evaluation rather than immediate regimen change.

Pregnancy‑specific guidance: Screen all pregnant women; obtain viral load in the third trimester for delivery planning (e.g., 34–36 weeks) and consider scheduled cesarean at 38 0/7 weeks if viral load >1,000 copies/mL or if viral load is unknown near delivery to reduce mother‑to‑child transmission.>1000 copies/mL

Guidance from ACOG/SMFM and referenced societies.

Standalone antigen assays are excluded and may be denied.

Note 1 (Frequency limits): Antibody and antigen/antibody testing should not be repeated more often than once every 90 days. Nucleic acid testing (qualitative or quantitative) should not be repeated more often than once every month.antibody/antigen ≤ once per 90 days; NAAT ≤ once per month

These frequency limits were consolidated into Note 1 in the 03/15/2026 revision.

Note 2 (Risk factors definition): Risk factors for HIV infection include: men who have sex with men (MSM), men who have sex with men and women (MSM/W), transgender individuals; sexual encounter with an individual with HIV; multiple sexual partners since last HIV test; sharing needles or injection equipment; exchanging sex for money or drugs; previous or concurrent STI, hepatitis, or tuberculosis; sexual partners with the above high‑risk factors or unknown sexual history.

New Note 2 added in the 03/15/2026 revision to operationalize elevated risk criteria for CC3.

Resistance testing viral load thresholds

EACS/BHIVA and DHHS recommend resistance testing preferably for HIV-VL >200-500 copies/mL and routinely for >500-1,000 copies/mL; consider testing even if 200-500 copies/mL as may be unsuccessful but still indicated.

Testing frequency notes

Antibody/antigen testing frequencyNo more often than once every 90 days (Note 1)

Nucleic acid testing frequencyNo more often than once per month (Note 1)

When requesting authorization or documenting medical necessity, cite the specific procedure code(s) and the clinical indication (e.g., entry to care, virologic failure, pregnancy).

Denial Risk

Risk of Unsuccessful Resistance Testing at Low Viral Loads

Resistance testing may be unsuccessful at low HIV RNA levels, but testing should still be considered in appropriate clinical contexts (e.g., HIV RNA >200 copies/mL; for 501–1,000 copies/mL testing may be unsuccessful but still considered). Document the reason for testing when viral load is low.

Risk of unsuccessful testing increases when HIV RNA is <500–1,000 copies/mL; for confirmed levels >200 but <1,000 copies/mL testing may be unsuccessful but should still be considered.
If testing is performed with low-level viremia, document the clinical rationale and that the provider understands potential for unsuccessful results.

Documentation Required

Testing Frequency Documentation

Follow the documented testing frequency limits in the policy: antibody/antigen testing should not be repeated more often than every 90 days; nucleic acid testing (NAAT; qualitative or quantitative) should not be repeated more often than once monthly.

Antibody and antigen/antibody testing: ≤ once every 90 days.
Nucleic acid testing (qualitative or quantitative): ≤ once monthly.

Documentation Required

Required Clinical Documentation for Viral Load and Resistance Testing

Document clinical indications and timing for viral load and resistance testing in the medical record. Include baseline viral load, indication (e.g., entry to care, virologic failure, pregnancy, ART modification), timing relative to ART initiation, and any prior ARV or PrEP exposure that might affect testing (e.g., prior CAB‑LA or INSTI exposure).

Required documentation: baseline HIV RNA level and date.
Indicate whether testing is entry-to-care, pre-ART, for virologic failure, suboptimal response, pregnancy-related management, or suspected ARV resistance.
Document prior ARV or PrEP exposure (including CAB‑LA or INSTI use) and adherence assessment when relevant.

Note

ART Initiation vs. Waiting for Resistance Results

In pregnancy, ART should be initiated before resistance results are available to reduce transmission risk; modify the regimen as needed once resistance assay results are reported. Similarly, for acute or recent infection and when initiating ART promptly, start ART without waiting for resistance results and adjust therapy after results return.

Initiate ART in pregnant people and in persons who will begin ART immediately; do not delay ART pending resistance results.
When ART is started before resistance results are available, document planned follow-up and intent to modify regimen if necessary based on assay results.

Step Therapy

Step Therapy — Informational

Step-therapy restrictions are not specified in the policy text for resistance testing or viral load monitoring. The policy provides informational guidance on monitoring frequency and criteria for performing resistance testing (e.g., thresholds for virologic failure) rather than step-therapy requirements.

No step-therapy requirements for testing are defined in this policy excerpt.
Informational: resistance testing recommended at entry to care and for virologic failure above specified HIV RNA thresholds; providers should document indication.

Clinical noteGenotype interpretation may be done by expert review or database correlation with phenotype

inv-43: Phenotypic assay

DefinitionPhenotypic assays measure the extent to which an antiretroviral drug inhibits viral replication (fold-change in susceptibility)

Use caseValuable for complex multidrug resistance when genotypic patterns are difficult to interpret

TechniqueOften uses recombinant virus assays inserting patient gene sequences into reference strains for measurement

inv-44: Fourth-generation Ag/Ab assay

Test typeFourth-generation antigen/antibody (Ag/Ab) combination immunoassay detects HIV-1/2 antibodies and p24 antigen

Recommended useRecommended as the initial laboratory HIV test due to earlier detection of acute infection

Follow-up actionsReactive Ag/Ab assays should be tested with an antibody differentiation assay; indeterminate results prompt NAT

inv-45: NAT

Definition and capabilityNucleic acid tests (NAT) detect HIV RNA and can detect infection earlier than antibody/antigen tests; used for acute diagnosis and viral load quantification

Diagnostic roleQualitative RNA NAT is FDA-approved for diagnosis of acute infection in antibody-negative persons; quantitative NATs are routinely used for monitoring

LimitationsNATs for HIV-1 do not detect HIV-2; plasma RNA is low in HIV-2 and RNA testing is unreliable for HIV-2 detection

inv-46: Window period

DefinitionWindow period = time between HIV exposure and when a given test can detect infection

ExamplesAntibody tests: 23–90 days; rapid Ag/Ab finger-stick: 18–90 days; Ag/Ab venous lab test: 18–45 days; NAT: 10–33 days

Clinical implicationIf initial test negative after exposure, retest after appropriate window period for the test used

inv-47: NAT (alternate entry)

DefinitionNAT detects HIV RNA (the virus) and can quantify viral load; useful for early detection and confirming acute infection

Regulatory noteA qualitative RNA test is FDA-approved for diagnosis of acute infection in antibody-negative persons; quantitative tests are used for monitoring

HIV-2 limitationHIV-1 RNA tests do not detect HIV-2; HIV-2 RNA/DNA testing requires different assays

inv-48: LDT

DefinitionLaboratory-developed tests (LDTs) are tests developed and validated in-house and regulated under CLIA as high-complexity tests

Regulatory statusLDTs are not FDA-approved or cleared, but FDA approval is not required for clinical use; labs must validate assays per CLIA

DocumentationPolicy notes reference FDA-approved assays but do not exclude clinical use of validated LDTs

inv-49: NAAT/RT-PCR

DefinitionNAAT/RT-PCR = nucleic acid amplification tests (including RT-PCR) used to detect and quantify HIV-1 RNA for diagnosis and monitoring

ExamplesFDA-approved platforms include COBAS TaqMan, Aptima, Alinity m for HIV-1 RNA quantitation and monitoring

Performance noteQuantitative NAATs have defined dynamic ranges and are intended for monitoring disease progression and ART response

Literature review did not necessitate modifications to coverage criteria.

2023-09-01material_revision

Literature review combined information from multiple prior HIV policies into a single policy and changed the policy title to 'Human Immunodeficiency Virus (HIV)'.